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Abstract
Background: Hepatitis D (or hepatitis delta) virus is a defective virus that relies on hepatitis B virus (HBV) for transmission;
infection with hepatitis D can occur only as coinfection with HBV or superinfection of an existing HBV infection. Because of
the bond between the two viruses, control measures for HBV may have also affected the spread of hepatitis D, as evidenced
by the decline of hepatitis D in recent years. Since the presence of hepatitis D is associated with suppressed HBV replication
and possibly infectivity, it is reasonable to speculate that hepatitis D may facilitate the control of HBV.
Methodology and Principal Findings: We introduced a mathematical model for the transmission of HBV and hepatitis D,
where individuals with dual HBV and hepatitis D infection transmit both viruses. We calculated the reproduction numbers of
single HBV infections and dual HBV and hepatitis D infections and examined the endemic prevalences of the two viruses.
The results show that hepatitis D virus modulates not only the severity of the HBV epidemic, but also the impact of
interventions for HBV. Surprisingly we find that the presence of hepatitis D virus may hamper the eradication of HBV.
Interventions that aim to reduce the basic reproduction number of HBV below one may not be sufficient to eradicate the
virus, as control of HBV depends also on the reproduction numbers of dual infections.
Conclusions and Significance: For populations where hepatitis D is endemic, plans for control programs ignoring the
presence of hepatitis D may underestimate the HBV epidemic and produce overoptimistic results. The current HBV
surveillance should be augmented with monitoring of hepatitis D, in order to improve accuracy of the monitoring and the
efficacy of control measures.
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Introduction
Hepatitis D (or hepatitis delta) virus is a defective virus that
requires helper functions from hepatitis B virus (HBV) for virion
assembly and propagation [1]. Therefore, infection with hepatitis
D can occur only with an associated HBV infection. This can
happen as coinfection (infection with both viruses at the same time)
or superinfection (where an already HBV-infected individual can
be infected with hepatitis D); individuals coinfected or superin-
fected transmit both viruses [2]. Transmission routes for hepatitis
D are similar to those for HBV, namely bloodborne and sexual,
percutaneous, permucosal, and perinatal. Superinfection with
hepatitis D is associated with higher progression rate to chronic
disease and to serious complications [3,2] and may result in
suppression of HBV replication, such that an individual with dual
infection transmits HBV less than an individual infected only with
HBV [4,5].
High prevalences of hepatitis D have been reported among
individuals infected with HBV, but recent reports indicate that
hepatitis D prevalence is on the decline. For instance, in 1986,
dual infection with both viruses was found in 91% of Taiwanese
drug users infected with HBV [6]; this percentage was reduced to
39% in 1997 [6]. In Italy the prevalence of hepatitis D among
HBV-infected individuals declined from 23% in 1987 to 8% in
1997 [7]. It is believed that the reductions in hepatitis D are largely
due to the reductions in HBV [7], as result of the introduction of
HBV vaccination and risk-reduction measures taken against the
spread of HIV: the decreased circulation of HBV decreases the
reservoir needed for the spread of hepatitis D, thus depriving the
defective virus of susceptible hosts to infect. Inversely, since
hepatitis D reduces the infectivity of HBV in those dually infected,
we could speculate that hepatitis D may facilitate the control of
HBV.
To investigate how hepatitis D affects the HBV epidemic, we
use a mathematical model describing the spread of the two viruses
in a population. We show that hepatitis D prevalence is very
sensitive to changes in the infectivity of HBV. We also show that if
hepatitis D virus is highly transmissible, the presence of hepatitis D
can result in more severe HBV epidemic.
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Methods
For the transmission of HBV and hepatitis D, we use a
mathematical model, shown in Fig. 1. Infection with hepatitis D
occurs only together with infection with HBV, as superinfection of
an existing HBV infection or coinfection with both viruses at the
same time. The infection is divided into two stages, a short acute
stage (stage 1) and a long chronic stage (stage 2) with lower
infectivity than the acute stage. Hepatitis D superinfection of an
individual already infected with HBV causes a generally severe
acute hepatitis with short incubation that usually leads to chronic
hepatitis [2]. Therefore, in the model those with acute or
chronic HBV infection who are superinfected with hepatitis D
go again through the acute phase (of dual infection). Let X be
the number of uninfected individuals, Yb1 and Yb2 the numbers
of persons infected only with HBV at stage 1 and 2, respectively,
and Ybd1 and Ybd2 the numbers of those infected with both
viruses. Let N~Xz
P
j~1,2 YbjzYbdj
 
be the total population
size. The model is described by the following differential
equations:
dX
dt
~B{mX{X GbzFbzFbdð Þ,
dYb1
dt
~X GbzFbð Þ{Yb1Fd{ mzhb1zcbð ÞYb1,
dYb2
dt
~cbYb1{Yb2Fd{ mzhb2ð ÞYb2,
dYbd1
dt
~XFbdz Yb1zYb2ð ÞFd{ mzhbd1zcbdð ÞYbd1,
dYbd2
dt
~cbdYbd1{ mzhbd2ð ÞYbd2,
ð1Þ
where we define the per capita risks to get
N infected only with HBV from an individual with single HBV:
Gb~
w
N
P
j~1,2
pbjYbj ,
N infected only with HBV from an individual with dual infection:
Fb~
w
N
P
j~1,2
qbj 1{qdj
 
Ybdj ,
Figure 1. Model for the transmission of hepatitis B virus (HBV) and hepatitis D virus (HDV).
doi:10.1371/journal.pone.0005247.g001
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N superinfected with hepatitis D: Fd~ wN
P
j~1,2
qdjYbdj ,
N c o i n f e c t e d w i t h b o t h H B V a n d h e p a t i t i s D :
Fbd~
w
N
P
j~1,2
qbjqdjYbdj .
The definitions of the parameters are summarised in Table 1.
The transmission probability of HBV from a person infected only
with HBV is pbj , for stage j = 1, 2. Persons infected with both
viruses in the j-th stage of infection, (i) transmit only HBV with
probability qbj 1{qdj
 
, (ii) transmit both HBV and hepatitis D
with probability qbjqdj , and (iii) superinfect those infected only with
HBV with probability qdj . Here it is assumed that hepatitis D may
affect the replication of HBV in individuals with dual infection,
such that those dually infected transmit HBV less than individuals
infected only with HBV [4,5]. With i= b for single HBV infection and
i = bd for dual infection, ci is the progression rate from stage 1 to stage
2, hi1 and hi2 are the progression rates out of stage 1 and stage 2
(recovery or extra death due to the disease). Also, Q is the rate of
partner change,m is the per capita removal rate out of the population,
and B is the rate at which new individuals enter the population.
Results
Conditions for the eradication or persistence of the
viruses
To investigate the long-term dynamics of the two viruses, we
performed an equilibrium analysis of the system equations. This
analysis allows us to find the steady state of the system and the
conditions for the eradication or persistence of the viruses. Solving
the model equations (1) with the left-hand side equal to zero, we
find all the possible steady states. The model has three types of
steady states: one where both viruses are eradicated (the disease-
free equilibrium), one where only HBV remains endemic but
hepatitis D is eradicated, and one where the prevalences of both
viruses are non-zero (in the following it will be shown that there
may be more than one point of this third type, with negative or
complex entries).
The reproduction numbers. Further, we found conditions
for the stability of the disease-free equilibrium and of the endemic
equilibria (see Supporting Information, Text S1, for details). These
correspond to conditions for the eradication or the persistence of
the viruses, respectively, and are expressed in terms of the
reproduction numbers. The basic reproduction number of HBV
(denoted Rb) is the number of secondary infections caused by an
individual with HBV throughout his infectious period, if
introduced in a population of uninfecteds. For this model, the
reproduction number of HBV is
Rb~
w
mzhb1zcb
pb1z
cbpb2
mzhb2
 
:
Similarly, we define the basic reproduction number of dual infections as
the number of secondary dual infections caused by an individual
with dual infection throughout his infectious period, if introduced
in a population of uninfecteds:
Rbd~
w
mzhbd1zcbd
qb1qd1z
cbdqb2qd2
mzhbd2
 
:
Finally, the invasion reproduction number of dual infections, R^bd , gives
the number of secondary cases of dual infections that an individual
with dual infection can produce throughout his infectious period, if
introduced in a population where HBV is at its endemic
equilibrium (see, e.g., [8]). This number is a threshold that
determines whether dual infection can invade the equilibrium with
only HBV and is given by
R^bd~
Rbd
Rb
z 1{
1
Rb
 
Rd
(see Text S1 for details of the calculations), where we used the
notation
Table 1. Parameter definitions and values.
Symbol Definition Value Source*
cb Progression rate from acute to carrier for HBV 0.4/person/year [27–29]
hb1 Recovery rate from acute infection with HBV 3.6/person/year [27–29]
hb2 Recovery rate from chronic infection with HBV 0.02/person/year [25,28]
pb1 Transmission risk of HBV from person with HBV only, stage 1 0.46 [25,30]
pb2 Transmission risk of HBV from person with HBV only, stage 2 0.65 pb1 [25,30]
cbd Progression rate from acute to carrier for those dually infected 2/person/year [2,28,31]
hbd1 Recovery rate from acute infection for those dually infected 2/person/year [2,28,31]
hbd2 Recovery rate from chronic infection for those dually infected 0.02/person/year [25,28]
qbj Transmission risk of HBV from person with dual infection, stage j= 1, 2 0.71 pbj [6]
qdj Transmission risk of hepatitis D from person with dual infection, stage j=1, 2 qbj
n Initial total population size 26000 [32]
m Rate of departing from the population 0.018/year
B Rate at which individuals enter the uninfected population mn
Q Rate of partner change 1.64 partners/year [33,34]
HBV, hepatitis B virus. Dually infected are individuals infected with both hepatitis B and hepatitis D viruses. The transmission risks are expressed as probabilities of
transmission per partnership. The stages 1 and 2 of infection (single HBV and dual) are the acute and the chronic stages, respectively.
*See details in the Supporting Information, text S1.
doi:10.1371/journal.pone.0005247.t001
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Rd~
w
mzhbd1zcbd
qd1z
cbdqd2
mzhbd2
 
:
Stability of equilibria. If both basic reproduction numbers Rb
and Rbd are less than one, the disease-free equilibrium is locally
asymptotically stable and otherwise it is unstable. If Rbw1 and
R^bdv1, then the endemic equilibrium with only HBV (hepatitis D
is eradicated) is locally asymptotically stable and unstable
otherwise. For the equilibrium with both viruses present, it was
not possible to find analytic conditions for its stability, due to the
complexity of the system. However, we solved numerically the
model equations for several combinations of the parameter values
and the numerical results suggest that the endemic equilibrium
with both HBV and hepatitis D is stable if either Rbd or R^bd is
greater than one (numerical calculations were done using
Mathematica, version 6.1). This implies that even if Rbv1,
HBV may not be eradicated if Rbdw1. (Notice that it is not
possible to have R^bdw1 while both Rb and Rbd are less than one,
because if Rbv1 then R^bdvRbd .) Figures 2 and 3 show that
indeed this is possible. The prevalences of the two viruses are
shown in Fig. 2A,C and the reproduction numbers in Fig. 2B,D for
different levels of infectivity during chronic HBV (pb2 is varied
from 0.01 to 0.4). If hepatitis D suppresses HBV replication
(Fig.2A,B), then HBV is eradicated when Rb is reduced below one.
However, if hepatitis D does not suppress HBV replication
(Fig. 2C,D), then reducing Rb below one is not sufficient to
eradicate HBV; the reproduction number of dual infections, Rbd ,
has to be also reduced below one.
Bistability: coexistence of endemic and disease-free
equilibrium. The condition that all reproduction numbers
are below one is necessary, but not sufficient for the eradication of
the viruses, as shown in Fig. 3. Here we solved numerically the
model equations (1) with the left-hand side equal to zero and
Figure 2. The impact of measures changing the infectivity of chronic hepatitis B virus (HBV). The transmission probability of chronic HBV
from individuals with single HBV infection (pb2) was varied from 0 to 0.4. A, B: hepatitis D reduces HBV infectivity by 50% in individuals dually infected
(qb2~0:5pb2); C, D: hepatitis D does not suppress HBV replication (qb2~pb2). Left panels show the total prevalence of HBV (black solid line), the
prevalence of hepatitis D (black dashed line), and the prevalence of HBV in a population without hepatitis D (grey line). Right panels show the
reproduction numbers Rb (solid line), Rbd (dashed line), and R^bd (dotted line).
doi:10.1371/journal.pone.0005247.g002
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calculated all the equilibrium points of the system, varying the
transmission risk from HBV carriers as in Fig. 2C,D (pb2 varied
from 0.01 to 0.4 and qb2~pb2, qb1~pb1). With these values the
system has five equilibrium points: the disease-free equilibrium, an
endemic equilibrium with only HBV, and three solutions with
non-zero prevalences for both HBV and hepatitis D. Of these last
three points, at least one is negative or complex for every value of
pb2 examined here, while two are positive for pb2 between 0.127
and 0.142. In this interval, Rb increases from 0.734 to 0.797, Rbd
from 0.906 to 1, and R^bd is negative. Also, with these values of pb2,
one of the positive points is locally asymptotically stable and the
other unstable, while the disease free equilibrium is also locally
stable (Fig. 3A; the two negative solutions and the complex values
are not shown). This suggests that the model exhibits backward
bifurcation, which means that an endemic and the disease-free
equilibria are both stable in an area where the associated
reproduction number is less than one. When pb2 exceeds 0.142,
Rbd becomes larger than one, and one of the two positive points
becomes negative. Fig. 3B shows HBV prevalence with
pb2~0:128, starting with different initial conditions: with the
Figure 3. Bistability: coexistence of endemic and disease-free equilibria. A. Bifurcation diagram. The two positive equilibria are shown with
black, the disease-free equilibrium with grey; solid lines correspond to locally asymptotically stable equilibria, dotted lines to unstable equilibria.
Results shown here are with pb2 varied from 0.12 to 0.15 (Rbd from 0.86 to 1.05), qb2~pb2 , qb1~pb1 , and the other parameters as in Table 1. B. The
prevalence of hepatitis B virus (HBV) with different initial conditions. In all curves shown, pb2~0:128, qb2~pb2 , qb1~pb1, and the other parameters as
in Table 1. The two positive endemic equilibria are at 9.83 (locally stable) and 4.88 (unstable).
doi:10.1371/journal.pone.0005247.g003
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same parameter values, the system converges to an endemic
equilibrium (HBV prevalence 9.83%) or to the disease-free
equilibrium, depending on the initial HBV prevalence.
How hepatitis D affects the spread of HBV
Variations in HBV prevalence according to hepatitis D
infectivity. The endemic prevalences of HBV and hepatitis D
are shown in Fig. 4A for a range of values of hepatitis D infectivity.
For comparison, we also calculated the endemic prevalence of
HBV for a hypothetical scenario where hepatitis D has not been
introduced in the population and only HBV is circulating. The
parameter values used relate to sexual transmission among men
having sex with men (see Table 1 and Text S1). If the
transmissibility of hepatitis D is very low, hepatitis D cannot be
sustained in the population and only HBV remains endemic. If
hepatitis D infectivity is sufficiently high, then both viruses remain
endemic and the prevalence of hepatitis D increases as its
infectivity increases. Comparing an epidemic where only HBV is
circulating (grey dotted line) with an epidemic where both HBV
and hepatitis D are circulating (black lines), and keeping the
properties of HBV otherwise equal, the following observations can
be made:
– If hepatitis D infectivity is not very high, the presence of
hepatitis D results in lower endemic HBV prevalence. This can
be understood intuitively, because now many individuals have
dual infection and transmit HBV less than individuals with
single HBV, resulting in less prevalent HBV infections.
– If hepatitis D infectivity is high, then hepatitis D spreads very
fast and, hence, despite the lower transmissibility of HBV in
those dually infected, those with single HBV infection are
superinfected sooner rather than later with hepatitis D and,
Figure 4. How the characteristics of hepatitis D affect the endemic prevalences of hepatitis B (HBV) and hepatitis D. The plot shows
the prevalences of HBV (solid line) and hepatitis D (dashed line) in a population where both viruses are circulating and the prevalence of HBV in a
population where only HBV is circulating (grey dotted line). A. The transmission probability of acute hepatitis D (qd1) was varied from 0 to 0.8 and
that of chronic hepatitis D (qd2)was 0.65 times that of acute hepatitis D. B. The percentage change in HBV infectivity in those dually infected
(compared to those with single HBV infection, 100  qbj{pbj
 
pbj , for j= 1, 2) was varied from 2100% to +50%. C, D. As in plots A, B, but assuming
that HBV carriers who are superinfected with hepatitis D do not re-enter acute HBV (using equations (2) instead of the last two equations of system
(1)).
doi:10.1371/journal.pone.0005247.g004
Hepatitis B and Hepatitis D
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hence, frequently during acute infection. Since the probability
of entering the chronic phase for those with acute dual
infection is five times higher than for those with acute single
infections, this results in higher endemic HBV prevalence and,
thus, in a more severe HBV epidemic.
Suppression of HBV replication due to hepatitis D. The
above results indicate that the suppression of HBV replication and
transmissibility due to hepatitis D infection in those dually infected
has an important role in the spread of the two viruses. To
investigate this further, the endemic prevalences of HBV and
hepatitis D were again calculated, but now for different levels of
suppression of HBV replication (Fig. 4B). If hepatitis D reduces
sufficiently the infectivity of HBV in those dually infected, the
presence of hepatitis D results in lower endemic HBV prevalence
and hence makes the HBV epidemic less severe. Otherwise, HBV
prevalence is higher than in the absence of hepatitis D, which
means that hepatitis D makes the HBV epidemic more severe.
Hepatitis D superinfection does not lead to acute
HBV. Further we investigated the assumption that HBV
carriers who are superinfected with hepatitis D go again through
acute HBV infection. Fig. 4C,D show the endemic prevalences of
HBV and hepatitis D, as in Fig. 4A,B, but assuming that HBV
carriers who are superinfected with hepatitis D go directly to
chronic dual infection. In this case, the last two of the model
equations (1) are substituted by the following equations:
dYbd1
dt
~XFbdzYb1Fd{ mzhbd1zcbdð ÞYbd1,
dYbd2
dt
~cbdYbd1{ mzhbd2ð ÞYbd2zYb2Fd ,
ð2Þ
This modification has two contradicting effects: (i) those
superinfected with hepatitis D are in total less infectious (because
they do not go through the acute phase); hence we would expect
less transmission of HBV and of hepatitis D; (ii) those
superinfected with hepatitis D now progress to chronic infection,
while only a fraction of them will progress from acute to chronic, if
superinfection leads to acute infection first; therefore we would
expect higher prevalence and higher transmission of HBV and of
hepatitis D. Fig. 4 shows that if carriers who are superinfected do
not re-enter the acute stage, the prevalence of hepatitis D is higher
and the virus remains endemic with lower infectivity. Also, the
prevalence of HBV is higher, even with lower hepatitis D
infectivity, since all superinfections become chronic infections
and there are no infections ‘‘lost’’ due to recovery from acute
infection, as explained also in Fig. 4A. This effect of hepatitis D on
HBV is diminished, resulting in lower HBV prevalence, only if
hepatitis D suppresses HBV infectivity too much in those dually
infected (for instance, more than 65% with the parameters
examined here), since then they can cause only too few new
infections. Therefore, the assumption that hepatitis D
superinfection causes HBV carriers to go again through the
acute HBV stage results in a milder epidemic than if they would
directly progress to chronic dual infection.
The impact of control measures for HBV
Here we examine the effect of control measures, such as
treatment, reducing the transmissibility of chronic HBV equally in
those with single (pb2) and those with dual infections (qb2). Since
antiviral agents have no effect on hepatitis D [9], the model
accounts for no reduction in infectivity of hepatitis D due to HBV
treatment. The intervention was introduced when the epidemic
had stabilised at the endemic equilibrium with both viruses
prevalent (with the parameters as shown in Table 1, where HBV
prevalence is slightly higher than what it would have been in the
absence of hepatitis D). By reducing the infectivity of HBV alone,
reductions in both HBV and hepatitis D can be achieved
(Fig. 5A,B). With the highest reductions in infectivity shown here
(40% and 50%), both viruses are eliminated; hepatitis D is
eliminated much earlier than HBV. For completeness, we
repeated the plots in Fig. 5A,B, assuming that treatment reduces
also the infectivity of hepatitis D (Fig. 5C,D). In this case, the
prevalence of hepatitis D declines much faster and the virus is
eradicated much earlier or it stabilizes at a lower endemic
prevalence (in the cases where it remains endemic). Also, the
prevalence of HBV is slightly lower.
Figure 2 shows how much HBV infectivity should be reduced in
order to eradicate HBV and hepatitis D. If hepatitis D suppresses
HBV replication (Fig. 2A,B), the control of HBV is not affected by
the presence of hepatitis D: HBV is eradicated with the same
reduction in HBV infectivity in both epidemics (with and without
hepatitis D). However, the resulting endemic prevalence is lower
than that in an epidemic without hepatitis D. In this case, hepatitis
D helps limiting the spread of HBV and enhances the impact of
the intervention. On the other hand, if HBV replication is not
suppressed by hepatitis D (Fig. 2C,D), higher reductions in HBV
infectivity are required to eradicate the viruses. Also, the resulting
endemic prevalence is higher than that in an epidemic without
hepatitis D. In this case, the presence of hepatitis D makes the
control of HBV more difficult and makes the interventions less
effective.
In many countries, surveillance of hepatitis D is limited and
therefore the actual prevalence of hepatitis D in the population is
unknown. For that reason, we examined the impact of a specific
intervention for HBV under different assumptions about the
‘‘unknown’’ prevalence of hepatitis D when the intervention was
introduced, but keeping the total prevalence of HBV constant
(Fig. 6). The intervention examined here is the reduction of the
transmission probabilities of chronic HBV by 20% for those with
single or dual infection. With higher hepatitis D prevalence at the
time the intervention is introduced, HBV prevalence is reduced
more, which means that in the beginning the intervention has a
higher impact. This can be explained by the fact that for those
with single HBV infection, infectivity is reduced by 20% due to
treatment, while for those with dual infection, it is reduced by 20%
on top of the 30% reduction due to suppression of HBV
replication. Therefore, the more individuals with dual infection
are present in the beginning (meaning, the higher the initial
hepatitis D prevalence), the higher the total reduction in HBV
infectivity and consequently the lower the prevalence of HBV. In
time, however, as hepatitis D prevalence declines due to treatment,
the effect of HBV replication also declines, and HBV prevalence is
finally lower without hepatitis D than in the presence of hepatitis
D.
Discussion
The results presented in this study indicate that the presence of
hepatitis D may have a strong impact on the spread of HBV.
Hepatitis D virus modulates both the severity of the HBV
epidemic and the impact of interventions that are aimed at
reducing HBV incidence. The presence of hepatitis D virus may
hamper the eradication of HBV. Interventions that aim to reduce
the basic reproduction number of HBV below one may not be
sufficient to eradicate the virus, as control of HBV depends also on
the reproduction numbers of dual infections. This implies that for
populations where hepatitis D is endemic, plans for control
Hepatitis B and Hepatitis D
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programs ignoring the presence of hepatitis D may underestimate
the HBV epidemic and produce overoptimistic results.
The impact of hepatitis D can be explained as follows. At the
individual level, hepatitis D affects HBV infection in two ways:
HBV transmission rate is lower and the chance to progress from
acute to chronic infection (and not recover) is higher for those with
dual infection than for those with single HBV infection. Because of
this, hepatitis D superinfection affects the prevalence of HBV at
the population level. If hepatitis D infectivity is high, then hepatitis
D superinfection will usually occur early during acute HBV
infection; that increases the chance to progress to chronic infection
and hence the prevalence of HBV. If hepatitis D infectivity is low,
then hepatitis D superinfection will mostly occur during chronic
HBV infection; that reduces HBV infectivity and hence HBV
prevalence. The precise mechanism depends on how much HBV
infectivity is reduced by hepatitis D, how much the progression rate to
chronic infection is increased by hepatitis D, and by other properties
of the two viruses. Our results, for instance, show that if hepatitis D
superinfection does not result in re-entering the acute stage, higher
HBV prevalence will be observed even with low hepatitis D
transmission rates. Unfortunately, knowledge about the properties
of dual infection is limited, as there are few studies on hepatitis D. The
use of a mathematical model allows us to incorporate existing
information and obtain realistic parameter values from the literature;
the uncertainty analysis of the model further shows how the outcomes
depend on the specific parameter values.
This study follows a considerable amount of research on the
epidemic dynamics of interacting pathogen strains (see, for
instance, [10–12]) and interacting pathogens (see, e.g., [13,14]).
Our results relate to those of other co-infections, for instance with
HIV and tuberculosis; the observations show that incidence of
tuberculosis has increased due to increased prevalence of HIV
infection [15,16]. The mechanism is that HIV impairs host
immunity and substantially alters the infection dynamics of
tuberculosis. Modeling studies have shown synergistic effects and
that antiviral treatment for HIV is necessary for the reduction of
Figure 5. How antiviral treatment reduces the prevalences of hepatitis B (HBV) and hepatitis D in time. A, B. Treatment reduces only
the infectivity of HBV. It is introduced at time 0, after the epidemic had stabilised at the endemic equilibrium with both viruses present, which is
shown with a straight grey line. The infectivity of chronic HBV is reduced by 20% (dotted lines), 30% (dashed-dotted lines), 40% (dashed lines), or 50%
(solid lines). Prevalences are shown as percentages of total population. C, D. As in plots A, B, but assuming that treatment reduces also the infectivity
of hepatitis D, by the same percentage as that of HBV.
doi:10.1371/journal.pone.0005247.g005
Hepatitis B and Hepatitis D
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tuberculosis prevalence [17,15]. However, the system studied here
is different in that hepatitis D is not a true pathogenic virus but
rather a subviral agent incapable of disseminating without help
from HBV. The requirement for a helper virus is a rare property
among human viruses. Only one other helper-dependent infec-
tious agent of humans is known (the adeno-associated virus, a
parvovirus that requires adenovirus as helper [18]). Although the
dynamics of a defective virus with a helper virus are reminiscent of
those of synergistic co-infection, they are essentially different in
that, whereas endemic equilibria of both tuberculosis without HIV
and HIV without tuberculosis are possible under specific
conditions, biology dictates that an endemic equilibrium with
only the defective virus but not the helper virus is impossible under
any circumstance.
The work presented here can be broadened towards several
interesting research directions. For instance, the model can be
extended to account for the effect of HBV vaccination. As yet,
there are no effective treatments specific for the hepatitis D
component of concurrent HBV and hepatitis D infections.
However, vaccination against HBV provides direct protection
against hepatitis D virus infection as well. In the recent years, HBV
vaccination has been introduced in many countries, resulting in
considerable reductions in HBV prevalence and incidence.
Moreover, vaccination reduces HBV transmission and, hence,
the number of those infected with HBV. As hepatitis D can be
transmitted only in the presence of HBV, the hepatitis D
prevalence will also decline. Our results for the treatment of
HBV infections lead us to expect that vaccination may also have a
large impact on the prevalence of hepatitis D. This expectation is
confirmed by observations in countries where HBV vaccination is
introduced and where hepatitis D is prevalent. For instance, in
Taiwan the national HBV vaccination of infants was introduced in
1984; 15 years later, the HBsAg carrier rate in children had
decreased from 9.8% to 0.7% [6]. The prevalence of hepatitis D
among Taiwanese drug users infected with HBV, the most
important risk group for hepatitis D transmission, decreased from
91% in 1986 to 39% in 1997 [6].
Further, it would be also interesting to account for stochasticity
in this framework. Several studies have shown that including
chance in the model can change its long-term behaviour, for
instance ‘‘fit’’ pathogens that remain endemic in the deterministic
model, may go extinct in the stochastic due to chance fading out
[19,20]. In models of multiple pathogen strains, it has been shown
that in cases where the deterministic model predicts the
coexistence of multiple strains, the stochastic model predicts the
extinction of one or all strains [21,22]. It is possible that a
stochastic analysis of the dynamics of HBV and hepatitis D would
also alter the results about the coexistence of the two viruses; this is
an area where future research should definitely receive more
attention.
An important direction for further work would be to include
spatial structure in the model. The assumption of proportionate
mixing in a large population ignores the clustering of individuals at
high risk. As both HBV and hepatitis D spread through the same
transmission routes, it is likely that there are clusters of individuals
with a high prevalence of HBV, where hepatitis D can disappear
by chance. To study the dynamics of such a system, we require a
meta-population model or a network model. It has been shown
that the dynamics of infection in such a network may differ, for
instance having less opportunity for persistence of the disease, or
greater possibility for extinction and limit cycles (see, e.g. [23,24]).
Our analysis presents a mean-field model of such a more complex
model and should be understood as a first step towards
understanding the complicated dynamics of interaction between
hepatitis D and HBV infection dynamics.
Another issue that could be investigated in further research is
the transmission of the two viruses via other contacts. In several
countries injecting drugs and household contacts are also
important routes of transmission of both HBV and hepatitis D
[6,7,25]. It is important to examine whether (and how) the
dynamics of the two viruses differ according to the route of
transmission and the risk groups in which they are prevalent. Also,
a number of studies have indicated that certain properties of
hepatitis D infection may be different in those superinfected with
hepatitis D compared to those who were infected with both viruses
at the same time (for instance, different progression rates [2]). The
model could be adapted to account for such differences, if those
dually infected are divided into two types, those superinfected and
those coinfected. Finally, the model can be extended to include a
separate subgroup of the population for those recovering from the
infection and becoming immune.
Finally, certain limitations of this modeling study have to be
mentioned. First, because of the limited knowledge on the
biological properties of hepatitis D and on how HBV infection is
changed in those dually infected, several assumptions were made
in the model structure or the parameter values used in the
numerical results. We tried to compensate the lack of data by
performing uncertainty analyses and examining different scenar-
ios, covering as much as possible of all realistic possibilities.
Another consideration is that we did not account for variation in
some progression rates of HBV according to age. This was done
because these rates are relatively stable for adults during the years
of sexual activity examined in the numerical results [26,27].
Therefore, it is expected that stratifying by age is not necessary and
would not affect considerably the results. Finally, in the present
study it was assumed that individuals recovering from HBV or
hepatitis D infection and those developing severe complications
are removed from the population and do not contribute further to
the transmission of the two viruses. Actually, those recovering
become immune, remain in the population, and may have
contacts with those not immune. Therefore, the total population
size is underestimated in the model and the incidence is
overestimated. However, this holds for both viruses and we expect
that it does not considerably affect the balance between the two
Figure 6. The initial impact of treatment on the prevalence of
hepatitis B (HBV). Antiviral treatment reduces infectivity of chronic
HBV by 20%. The total prevalence of HBV is shown as percentage of the
population. When the intervention is introduced (year 0), 36% of the
population is infected with HBV; among them, the percentage
coinfected with hepatitis D is 30% (solid line), 20% (dashed line), 10%
(dashed-dotted line), or 0% (dotted line).
doi:10.1371/journal.pone.0005247.g006
Hepatitis B and Hepatitis D
PLoS ONE | www.plosone.org 9 April 2009 | Volume 4 | Issue 4 | e5247
viruses or their interaction. This simplification allows us to sketch
the expected qualitative dynamic behavior and the potential
impact that hepatitis D has on the spread and control of HBV.
To our knowledge, this is the first attempt to model the
dynamics of hepatitis D and to investigate the interplay between
HBV and hepatitis D. On the empirical side, there is very little
known about the epidemiological properties of hepatitis D, and
given its importance in affecting the HBV epidemic, more
information is needed on basic epidemiological characteristics of
hepatitis D infection and the time course of infection with HBV
and a concurrent hepatitis D infection. On the theoretical side,
understanding the complex dynamics of the interaction between a
defective virus and its helper virus would be much helped by
additional modeling approaches that incorporate the role of
demographic stochasticity and network models. Our findings
indicate that hepatitis D plays an important role in the spread and
control of HBV. Investigating the transmission dynamics of HBV
should account for the presence of hepatitis D in a population.
Augmenting the existing HBV monitoring programs with
monitoring of hepatitis D could boost the accuracy of the
surveillance of HBV prevalence and of the efficacy of control
programs.
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